Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968769 | 0.84 | ALDH1A1 (0.37) | ALDH1A1CYP2C9 | |
| SCHEMBL24495306 | 0.79 | ALDH1A1 (0.35) | ALDH1A1CYP2C9 | |
| SCHEMBL23818194 | 0.78 | ALDH1A1 (0.30) | ALDH1A1CYP2C9 | |
| SCHEMBL20462593 | 0.74 | ALDH1A1 (0.31) | ALDH1A1CYP2C9 | |
| SCHEMBL20464252 | 0.74 | ALDH1A1 (0.34) | ALDH1A1CYP2C9 | |
| SCHEMBL16016678 | 0.71 | — | — | |
| SCHEMBL10159729 | 0.69 | — | — | |
| SCHEMBL5946714 | 0.69 | ADORA2A (0.34) | — | |
| SCHEMBL12778936 | 0.69 | NPC1 (0.32) | ALDH1A1CYP2C9L3MBTL1 | |
| SCHEMBL21719365 | 0.67 | AOC3 (0.32) | ALDH1A1CYP2C9L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | US | disclosed |
| US-9839639-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | ALDH1A1 4441/4885CYP2C9 4734/4885L3MBTL1 3385/4885 |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | ALDH1A1 4405/4885CYP2C9 4713/4885L3MBTL1 3386/4885 |
| US-20210002236-A1 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | RIPK1, RIPK2, RIPK3 | ALDH1A1 4505/4885CYP2C9 4879/4885L3MBTL1 1049/4885 |
| US-11370764-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | ALDH1A1 4505/4885CYP2C9 4879/4885L3MBTL1 1049/4885 |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ALDH1A1 2655/4885CYP2C9 1674/4885L3MBTL1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.